In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. | A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine nab-paclitaxel in elderly pancreatic cancer patients GrantPax